EP Lab Digest Features Physician Experience with BioSig’s Cardiac Signal Acquisition Technology
April 08 2021 - 8:32AM
- Leading industry publication highlights the rising
importance of intracardiac signals in complex cardiac ablations
that treat irregular heart rhythm disorders
- High-quality intracardiac signals are deemed essential
to determine ablation endpoints
- PURE EP™’s signals are described as ‘indispensable’ by
the physician user
BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the
"Company"), a medical technology company commercializing an
innovative signal processing platform designed to improve signal
fidelity and uncover the full range of ECG and intra-cardiac
signals, today announced the PURE EP™ System was highlighted in a
feature interview for the April issue of EP Lab Digest, a leading
industry publication for electrophysiology professionals.
EP Lab Digest interviewed Deepak Gaba, MD, clinical
electrophysiologist, and Shari Slyder, BS, RT, Managing Director of
Cardiovascular Services, who currently use the PURE EP™ System at
Memorial Hospital in South Bend, Indiana. The feature interview
titled ‘Improved Intracardiac Signal Visualization During RF and
Cryo Procedures’ highlighted the rising importance of intracardiac
signals in complex ablations and the process of incorporating the
PURE EP™ System into the practice at Memorial Hospital that
conducts 480 EP cases annually.
According to Dr. Gaba and Mrs. Slyder, the ability to accurately
discern local and far-field electrograms is essential for
identifying arrhythmia substrate and guiding ablation endpoints. As
the new high-density catheters and advanced electrode designs enter
the market, there is a renewed focus on acquiring and displaying
high-fidelity intracardiac signals. Dr. Gaba, who, along with his
colleagues, has performed more than twenty-five procedures using
PURE EP™ to date, describes the superior quality of PURE EP™
signals in different clinical scenarios using both Cryo and
radiofrequency energy. Dr. Gaba further highlights that the signals
acquired with the PURE EP™ System affect his decisions about
arrhythmia's origination and optimal site of energy delivery.
Additionally, Shari Slyder, a certified radiologic technician
(AART), elaborates on the advantages of PURE EP™’s advanced noise
shielding capabilities—a unique feature of its proprietary
architecture. Read the full article here.
"As we continue expanding our clinical footprint, we are rapidly
learning how the cardiac information provided by PURE
EP™ complements other technologies and elevates the experience
in the electrophysiology lab. The growing physician acceptance of
our technology is a result of our dedication to addressing unmet
clinical needs. We are pleased to see the increased industry’s
focus on the importance of high-fidelity intracardiac signals
across all types of cardiac arrhythmias," commented Olivier
Chaudoir, Senior Director of Marketing at BioSig Technologies,
Inc.
The PURE EP™ System is being used in all types of
arrhythmia cases, including atrial fibrillation, ventricular
tachycardia, and atrial flutter. More than 680 patient cases have
been conducted with the technology to date. The Company continues
to accumulate significant amounts of data to be utilized in the new
product development to complement the PURE EP™ System,
including AI- and machine learning-powered applications and modules
for electrophysiology. The article is the latest interview in a
series of publications featuring BioSig’s PURE EP™ System in
industry-leading media outlets. Previous publications include a
January 2021 editorial by EP Lab Digest’s Editor-in-Chief, Bradley
P. Knight, M.D., FACC, FHRS, a December 2020 feature
interview with Rafaelle Corbisiero, M.D. and Pedram Kazemian,
M.D. of Deborah Heart and Lung Center, and an April
2020 interview with Andrea Natale, M.D. of Texas Cardiac
Arrhythmia Institute at St. David’s Medical Center.
About BioSig Technologies BioSig Technologies
is a medical technology company commercializing a proprietary
biomedical signal processing platform designed to improve signal
fidelity and uncover the full range of ECG and intra-cardiac
signals (www.biosig.com).
The Company’s first product, PURE EP™ System, is a computerized
system intended for acquiring, digitizing, amplifying, filtering,
measuring and calculating, displaying, recording and storing of
electrocardiographic and intracardiac signals for patients
undergoing electrophysiology (EP) procedures in an EP
laboratory.
Forward-looking Statements This press release
contains “forward-looking statements.” Such statements may be
preceded by the words “intends,” “may,” “will,” “plans,” “expects,”
“anticipates,” “projects,” “predicts,” “estimates,” “aims,”
“believes,” “hopes,” “potential” or similar words. Forward- looking
statements are not guarantees of future performance, are based on
certain assumptions and are subject to various known and unknown
risks and uncertainties, many of which are beyond the Company’s
control, and cannot be predicted or quantified and consequently,
actual results may differ materially from those expressed or
implied by such forward-looking statements. Such risks and
uncertainties include, without limitation, risks and uncertainties
associated with (i) the geographic, social and economic impact of
COVID-19 on our ability to conduct our business and raise capital
in the future when needed, (ii) our inability to manufacture our
products and product candidates on a commercial scale on our own,
or in collaboration with third parties; (iii) difficulties in
obtaining financing on commercially reasonable terms; (iv) changes
in the size and nature of our competition; (v) loss of one or more
key executives or scientists; and (vi) difficulties in securing
regulatory approval to market our products and product candidates.
More detailed information about the Company and the risk factors
that may affect the realization of forward-looking statements is
set forth in the Company’s filings with the Securities and Exchange
Commission (SEC), including the Company’s Annual Report on Form
10-K and its Quarterly Reports on Form 10-Q. Investors and security
holders are urged to read these documents free of charge on the
SEC’s website at http://www.sec.gov. The Company assumes no
obligation to publicly update or revise its forward-looking
statements as a result of new information, future events or
otherwise.
Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
54 Wilton Road, 2nd floor
Westport, CT 06880
aballou@biosigtech.com
203-409-5444, x133
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Apr 2024 to May 2024
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From May 2023 to May 2024